Lyrica (pregabalin) is classified as a gabapentinoid, a type of nerve pain and anti-seizure medication. It belongs to a broader category sometimes called anticonvulsants or antiepileptics, but it works differently from most drugs in that group. In the U.S., it is also a Schedule V controlled substance, the lowest level of federal drug scheduling, because of its potential for misuse.
How Lyrica Is Classified
Pregabalin is a synthetic molecule structurally related to GABA, a chemical the brain uses to calm nerve activity. Despite that structural resemblance, it doesn’t actually work on GABA receptors. Instead, it binds to a specific part of calcium channels on nerve cells called the alpha-2-delta subunit. This is why you’ll sometimes see it described as an “alpha-2-delta ligand” in medical literature.
Lyrica shares this mechanism with gabapentin (Neurontin), and together they form the gabapentinoid class. The two drugs target the same site but differ in important ways. Pregabalin has a bioavailability of 90% or higher regardless of dose, meaning nearly all of it reaches your bloodstream. Gabapentin’s absorption drops from about 60% to 33% as the dose increases. Pregabalin is also roughly 2.5 times more potent based on the drug levels it produces in the blood.
What It Does in the Body
Lyrica’s key feature is that it selectively targets overexcited nerve cells. When a nerve is firing too aggressively, as happens in chronic pain conditions or seizure disorders, pregabalin binds to those hyperactive calcium channels and reduces the flow of calcium into the nerve terminal. Less calcium means the nerve releases fewer excitatory chemical signals. The result is that overactive nerves quiet down toward a normal state, while nerves functioning normally are largely left alone.
This state-dependent action is part of what makes pregabalin useful across several conditions. It reaches peak levels in the blood within about 1.5 hours of taking it and has a half-life of around 6 hours, meaning your body clears it relatively quickly. It’s eliminated mostly through the kidneys rather than being broken down by the liver.
FDA-Approved Uses
Lyrica is approved in the U.S. for five conditions:
- Diabetic nerve pain (peripheral neuropathy), the burning or tingling in hands and feet caused by diabetes
- Postherpetic neuralgia, the lingering nerve pain that can follow a shingles outbreak
- Fibromyalgia, a condition involving widespread musculoskeletal pain
- Spinal cord injury pain, specifically neuropathic pain resulting from damage to the spinal cord
- Partial-onset seizures, used alongside other seizure medications in patients one month of age and older
Outside the U.S., pregabalin is also approved for generalized anxiety disorder in several countries, though that use remains off-label in America. Doctors sometimes prescribe it off-label for chronic low back pain and other nerve-related pain conditions as well.
Why It’s a Controlled Substance
When the DEA placed pregabalin into Schedule V in 2005, the rationale centered on its ability to produce euphoria. Clinical trial data showed an unusually high percentage of participants experiencing euphoric effects, and the drug produced some of the same subjective feelings as benzodiazepines like diazepam and alprazolam. In lab studies, animals self-administered pregabalin at rates higher than a placebo, though substantially lower than stronger sedatives.
Schedule V is the least restrictive controlled category. The DEA determined that pregabalin has a low abuse potential relative to Schedule IV drugs and that any physical or psychological dependence it causes is limited by comparison. Still, the scheduling means prescriptions are tracked, and pharmacies may have additional requirements for dispensing it.
Common Side Effects
Dizziness and drowsiness are by far the most frequent side effects. In controlled studies, 24 to 30% of adults taking Lyrica experienced dizziness, and 16 to 23% experienced drowsiness. These tend to be most noticeable when you first start the medication or after a dose increase.
Other side effects occurring in at least 5% of patients include dry mouth, swelling in the hands or feet, blurred vision, weight gain, and difficulty concentrating. Side effects are dose-dependent, meaning higher doses produce more of them. For diabetic nerve pain, doses above 300 mg per day don’t appear to add significant benefit but do increase side effects. For fibromyalgia, the ceiling is 450 mg per day.
Withdrawal and Stopping Safely
Stopping Lyrica abruptly can cause withdrawal symptoms, typically appearing within 48 hours. The most commonly reported symptoms include anxiety, insomnia, nausea, sweating, dizziness, headache, tremor, and low mood. How intense these are depends on how much you’ve been taking and for how long.
Gradual tapering is the standard approach. A typical recommendation is reducing the dose by 5 to 10% every two to six weeks, recalculating at each step. For pregabalin specifically, reductions generally should not exceed 50 to 100 mg in a single week. The process can take weeks to months for people who have been on higher doses for extended periods.
Safety Warnings to Know About
Like all anti-seizure medications, Lyrica carries a warning about suicidal thoughts and behavior. The risk is small, roughly 1 in 500 people, but it applies across all conditions the drug treats, not just epilepsy. New or worsening depression, anxiety, agitation, panic attacks, and unusual mood changes are all signals worth paying close attention to, particularly in the first few months or after dose changes.
Serious allergic reactions are rare but possible. Swelling of the face, mouth, lips, or throat, difficulty breathing, and skin reactions like hives or blisters are signs that require immediate medical attention.